| Literature DB >> 30674838 |
João Basso1,2, Ana Miranda3,4, Sandra Nunes5, Tânia Cova6, João Sousa7,8, Carla Vitorino9,10,11, Alberto Pais12.
Abstract
Chemotherapy is commonly associated with limited effectiveness and unwanted side effects in normal cells and tissues, due to the lack of specificity of therapeutic agents to cancer cells when systemically administered. In brain tumors, the existence of both physiological barriers that protect tumor cells and complex resistance mechanisms to anticancer drugs are additional obstacles that hamper a successful course of chemotherapy, thus resulting in high treatment failure rates. Several potential surrogate therapies have been developed so far. In this context, hydrogel-based systems incorporating nanostructured drug delivery systems (DDS) and hydrogel nanoparticles, also denoted nanogels, have arisen as a more effective and safer strategy than conventional chemotherapeutic regimens. The former, as a local delivery approach, have the ability to confine the release of anticancer drugs near tumor cells over a long period of time, without compromising healthy cells and tissues. Yet, the latter may be systemically administered and provide both loading and targeting properties in their own framework, thus identifying and efficiently killing tumor cells. Overall, this review focuses on the application of hydrogel matrices containing nanostructured DDS and hydrogel nanoparticles as potential and promising strategies for the treatment and diagnosis of glioblastoma and other types of brain cancer. Some aspects pertaining to computational studies are finally addressed.Entities:
Keywords: drug delivery; glioblastoma; hydrogel; hydrogel nanoparticles; local treatment; nanostructured drug delivery system
Year: 2018 PMID: 30674838 PMCID: PMC6209281 DOI: 10.3390/gels4030062
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Figure 1Administration of hydrogels for glioblastoma (GBM) and/or other brain tumors treatment. (A) Local delivery of nanostructured systems loaded in a macroscopic hydrogel matrix, via intratumoral injection or implant after surgical resection. Note that a controlled and localized release of the therapeutic agent over time is claimed. (B) Intravenous administration of hydrogel nanoparticles with surface functionalization as an active targeting strategy.
Hydrogel-based system as therapeutic or diagnostic strategies against brain tumors.
| Delivery System | Hybrid System | Carried Agent | Route of Admin. | Trigger | Main Achievements | Ref. |
|---|---|---|---|---|---|---|
|
| ||||||
|
| PEG750-p(CL- | TMZ | Local Delivery | UV light | Fast in situ photopolymerization; sustained release of TMZ over 1 week; potent in vivo antitumor efficacy. | [ |
| mPEG-PDLLA micelles + macroporous gelatin hydrogel | PTX | Local Delivery | Enzymatic | Controlled release of PTX and high inhibition of tumor cell proliferation in glioma C6 cells. | [ | |
| HA NPs + collagen hydrogel | Lentivirus | Local Delivery | - | HA within the hydrogel increased the lentivirus activity for 72 h and delayed its release; Transduction activity in invasive C6 glioma cells with the hydrogel was ~80% of the control. | [ | |
| BSA NPs + CMC- | PTX + EPI | Local Delivery | Temp. | MBR 614 cell line: sustained drug release and inhibition of tumor cells growth; human glioma U87 MG tumor-bearing mouse: effective tumor reduction and average survival increase. | [ | |
| Silica NPs + PEG-based hydrogel | CPT | Local Delivery | UV light | U87 MG cells: marked decreased in cell viability. | [ | |
| mPEG-PLGA NPs + PF127 hydrogel | PTX + TMZ | Local Delivery | Temp. | Drug release was controlled by gel composition; High growth inhibition and apoptosis-inducing effects in both U87 MG and C6 cell lines. | [ | |
|
| Fe3O4 NPs + PEG-based hydrogel | PTX | Local Delivery | AMF | Effective delivery of PTX simultaneously with hyperthermia in M059K glioma cells. | [ |
| P-CoFe2O4 NPs + PPZ hydrogel | SN-38 | Local Delivery | - | Drug sustained release; long-term inhibition of tumor growth in U87 MG tumor-bearing mice; proved MR imaging abilities. | [ | |
|
| Liposomes + P(NIPAAm- | DOX | Local Delivery | Temp. | Increased sustained release over 52 days; Significant reduction of tumor growth (38 days vs. 12 days with free DOX in hydrogel). | [ |
|
| Lipid nanocapsule-based hydrogel | GemC12 | Local Delivery | - | Sustained drug release over one month with a significant increase of survival/reduction of recurrences in tumor xenograft models. | [ |
|
| Anti-EGFR-SLNs + in situ gel | CP | Intranasal | - | The optimized formulation presented good viscosity, gelling strength, drug content as well as favorable adhering properties to the nasal mucosa, stability and dissolution profile, among others. | [ |
|
| ||||||
|
| Polyglycerol-scaffold nano-polyplexes in polymeric nanogels | miR-34a | Local Delivery | pH/redox | Significant reduction in tumor size growth of abdominal GBM xenograft models. | [ |
| Liposome-templated hydrogel NPs | CRISPR/Cas9 | IV | - | Controlled release of DNA and protein; Marked cytotoxicity over U87 MG cells; reduction of tumor growth and improvement of overall survival of mice models. | [ | |
| PEI-modified PAA-based hydrogel NPs | CIS | - | - | Uptake of nanogels promoted by PEI-9L glioma cells interaction; higher toxicity of NPs over glioma cells than free CIS. | [ | |
| Fe3O4 NPs loaded MPNA nanogel | Cy5.5 | IV | pH/Temp. | Proved MR/fluorescence imaging abilities; Good and specific uptake by C6 glioma cells in rat model; cellular uptake favored at pH 6.8 (tumor environment) using lactoferrin. | [ | |
| PAA-based hydrogel NPs | CB | IV | - | Covalently linked CB nanoparticles, functionalized with F3 peptide and PEG, effectively target and clearly identify GBM cells. | [ | |
| F3 peptide-conjugated co(CEA-AAm) nanogel | DOX | - | - | Surface modification with F3 peptide increased NPs uptake by 9 L glioma cells; NPs show controlled release of DOX (42% in the first 24 h). | [ | |
| Anti-Cx43 and anti-BSAT1-conjugated nanogels | CIS | IV | - | Sustained release of CIS (50% after one week); Despite the lower cytotoxicity over C6 cells than free CIS, NPs improved the overall survival of 101/8 cells implanted in rats. | [ | |
| cRGD-decorated PVA nanogels | DOX | IV | pH/redox | Triggered release of DOX caused by low pH and redox environment; cRGD modified nanogels effectively reduce tumor growth in vivo. | [ | |
| Alginate nanogel co-loaded with gold nanoparticles | CIS | - | X-Ray | Higher toxicity on U87 MG cells, when compared to free CIS; marked apoptotic effect after X-ray irradiation. | [ | |
| Fe3+-crosslinked pentaerythritol poly-(caprolactone)- | DOX | IV | Light | Nanoparticles effectively release DOX after the exposure of the tumor to light, with 91% of tumor growth inhibition and no adverse effects. | [ | |
|
| ||||||
|
| PLGA microspheres + TGP hydrogel | CPT | Local Delivery | Temp. | Sustained drug release of CPT at the tumor site; hydrogel administration and tumor resection significantly increased overall survival of the models (over 60 days). | [ |
| PLGA microspheres + alginate hydrogel | PTX | Local Delivery | - | After a low initial burst, microspheres exhibited a controlled drug release over more than 60 days; higher cytotoxicity over C6 cells when compared to reference; reduction of tumor volume in tumor-bearing models. | [ | |
| PLGA microspheres + P(NIPAAm- | DOX | Local Delivery | Temp. | Increased sustained release over 30 days; significant reduction of tumor growth (32 days vs. 12 days with free DOX in hydrogel). | [ | |
Key: PEG750-p(CL-co-TMC) = poly(ethylene glycol) 750-(poly(ε-caprolactone-co-trimethylene carbonate)); PEG = poly(ethylene glycol); DMA = dimethacrylate; TMZ = temozolomide; UV = ultraviolet; mPEG = methoxypoly(ethylene glycol); PDLLA = poly(d,l-lactide); PTX = paclitaxel; C6 cells = rat glioma cells; HA = hydroxylapatite; NPs = nanoparticles; BSA = bovine serum albumin; CMC-g-PNIPAAmMA = carboxymethyl cellulose (CMC)-grafted poly(N-isopropylacrylamideco-methacrylic acid); DTPAGd/bPEI = gadopentetic acid/branched polyethylenimine; EPI = epirubicin; Temp. = temperature; MBR 614 cell line = human brain tumor cells; U87 MG = human likely glioblastoma cells; CPT = camptothecin; PLGA = poly(lactic-co-glycolic acid); PF127 = Pluronic® F127; AMF = alternating magnetic field; M059K glioma cells = human brain malignant glioblastoma cells; P-CoFe2O4 = PEGylated cobalt ferrite; PPZ = poly(organophosphazene); SN-38 = 7-ethyl-10-hydroxycamptothecin; MR = magnetic resonance; P(NIPAAm-co-BMA) = poly(N-isopropylamide-co-n-butylmethacrylate); DOX = doxorubicin; LNC = lipid nanocapsule; GemC12 = lauroyl-gemcitabine (prodrug); SLNs = solid lipid nanoparticles; EGFR = epidermal growth factor receptor; CP = Cyclophosphamide; miR-34a = microRNA encoded by the human MIR34A gene and recognized as a regulator of tumor suppression; GBM = glioblastoma; CRISPR/Cas9 = Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated protein 9 system; IV = intravenous; DNA = deoxyribonucleic acid; PEI = polyethylenimine; PAA = polyacrylamide; CIS = cisplatin; 9 L glioma cells = rat gliosarcoma cells; MPNA = poly(N-isopropylacrylamide-co-acrylic acid; Cy5.5 = Cyanine5.5 NHS; CB = Coomassie Brilliant Blue G-250; F3 peptide = 31 amino acid peptide with tumor homing capability; co(CEA-AAm) = 2-carboxyethyl acrylate-acrylamide copolymer; Cx43 = Gap junctional protein Connexin 43; BSTAT1 = brain-specific anion transporter; 101/8 cells = rat glioblastoma cells; cRGD = cyclo(Arg-Gly-Asp) peptide; PVA = poly(vinyl alcohol); PLGA = poly(d,l-lactide-co-glycolide); TGP = thermoreversible gelation polymer.
Figure 2Schematic illustration depicting a poly(ethylene glycol) (PEG) based-hydrogel matrix loaded with silica nanoparticles. Upon photo-irradiation of the hydrogel, covalently bounded camptothecin (CPT) is effectively released, thus inducing U78 MG cell death. Retrieved from ref. [32] with permission from Royal Society of Chemistry.
Figure 3Schematic illustration of polymer gel frameworks containing nanoparticles, including a chemically crosslinked network with (a) entrapped particles and (b) the physical interactions between magnetic particles and polymer, (c) a hybrid network with particle crosslinkers, and (d) micelles loading magnetic particles.
Overall features assigned to hydrogel nanoparticles with impact on drug delivery [80,84].
| Critical Quality Attributes | Justification |
|---|---|
| Easy to synthetize | They can be easily scaled up for large-scale production, in addition to being an eco-friendly chemistry approach. |
| Nanosize | Their small size eases the passage through biological barriers and avoids clearance by phagocytic cells, thus increasing their blood circulation time. |
| Viscoelasticity | Given their ability to deform, i.e., to switch between solid-like and liquid-like states, hydrogel nanoparticles pass more easily through biological barriers and cell membranes. |
| Swelling capacity | Occurring in aqueous fluids, swelling is controlled by chemical structure of the gel matrix and its crosslinking degree, as well as environmental variables (temperature, pH and ionic strength). |
| Response to stimuli | They can respond to biological stimuli, ensuring site-specific and controlled release of drugs. Such response involves changes in physicochemical properties of the hydrogel nanoparticles (swelling, permeability, viscoelasticity). |
| Encapsulation stability | Their crosslinked structure allows an extend drug circulation time in bloodstream, protecting drugs from enzymatic/chemical degradation. |
| Passive and active targeting | A wide range of bioactives (drugs, peptides, proteins, antibodies and vaccines) can be coupled to the surface of hydrogel nanoparticles in order to target specific tissues. In addition, stimuli-responsive hydrogels (as referred above) are another strategy of active targeting. Extravasation in the pathological sites and retention in the microvasculature could represent passive targeting approaches of hydrogel nanoparticles. All of them increase therapeutic efficacy and reduce undesired effects. |
|
| Internal crosslinking modulation of hydrogel nanoparticle networks can control both drug loading capacity and drug release. |
| Minimal toxicity | They are biocompatible, non-immunogenic and biodegradable. |
Figure 4Schematic representation of the production of the liposome-templated hydrogel nanoparticles. (a) Cross-linking mediated by cyclodextrin-amantadine host-guess interaction of the polyethylenimine (PEI) chains. (b) Hydrogel nanoparticle structure contemplating a hydrogel core encapsulated by a 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) shell. Retrieved from ref. [42] with permission from Wiley Online Library.
Figure 5(I) Representation of the molecular structures and the simulation systems including (I-a) TNFR1 and TNFR2 composed of four cysteine-rich domains; (I-b) the co-crystalized structure between TNFR2 and TNFα; (I-c) the initial configurations for MD simulations, containing 10 Gd@C82(OH)22 per protein in water. (II-a) Site-specific Gd@C82(OH)22 contacts with TNFα; (II-b) Potential of mean force (PMF) for Gd@C82(OH)22 binding to TNFα, projected onto the surface of TNFα. (III-a) Site-specific contacts with TNFR1 and TNFR2; (III-b) PMF projection onto the protein surface. (III-c) Illustration of a representative trajectory corresponding to the binding of Gd@C82(OH)22 and TNFR1. (III-d) Illustration of the binding mode for TNFR1. Retrieved from ref. [121] with permission from Elsevier.
Figure 6A composed view of the network components and of the inclusion complexes used as junction nodes. (I,II) PMF profiles for the inclusion complexes between the hyaluronic acid derivatives, (IV) 2D scatter plots for the most stable complex, corresponding to the deepest minimum (left) and to the higher-lying local minimum (right) of the PMF profiles depicted in panel (III) (D and D′, respectively). The 3D molecular images for the equilibrium states of the complexes, showing different types and strengths of noncovalent interactions between the system components are also included. Retrieved from ref. [124] with permission of American Chemical Society.
Figure 7(I) Representative configurations of the crosslinked network at the principal structural parameter (cpc) of 0.00. Dark blue: strongly physically interacting groups, light blue: shells of clusters, gray: flexible chains. (I-a) dry phase of the simulation box, (I-b) the clusters, (I-c) the flexible chains. (II) Schematic representation of the models reported in (II-a) literature and by the authors (II-b), the latter describing physically/chemically crosslinked networks. Different recovery modes of the structure are also illustrated and include the (II-c) exchange of atomic groups between clusters, and the (II-d) reshaping of clusters by dissociation and association to the same cluster. (III) Snapshots of hybrid networks showing the chemical crosslinks (red) at cpc values of 0.7 (III-a) and 3.05 (III-b). The physically interacting groups without chemical crosslinks are represented in dark blue, while those with chemical crosslinks in their vicinity are in green. Retrieved from ref. [126] with permission from Elsevier.
Figure 8Representative microgel configurations obtained from the simulations of the microgels with magnetic particles (red), considering different degrees of crosslinking (Ncros = 20, panels (a,c,e), Ncros = 200, panels (b,d,f)) and different strengths of dipolar interactions λ (1–8). Retrieved from ref. [128] with permission from Elsevier.